Impulse Dynamics and MetaCure Sign Asia-Pacific Distribution Agreements With Vitality Devices
Vitality was established by Australian biotechnology entrepreneurs Dr. Greg Collier and Dr. James Campbell, who previously served as the executive management team of the drug development company ChemGenex Pharmaceuticals from 2002, guiding its growth, clinical development and ultimate sale to Cephalon Inc. in 2011. Vitality will specialize in commercializing medical technology in the Asia Pacific region; it will focus on the Impulse Dynamics and MetaCure implants as the cornerstone of its commercial platform, adding additional medical devices over time.
“We view our partnership agreement with Vitality as a strategic asset,” said Impulse Dynamics and MetaCure CEO, Dr. Irit Yaniv. “With the growing incidence of Chronic Heart Failure and Metabolic Disease throughout the Asia Pacific region, we view these markets as a primary commercial target and source of growth for our companies”.
Impulse Dynamic’s Optimizer III and MetaCure’s Diamond System represent technological advancement in device based disease treatment. The Optimizer III implant uses Cardiac Contractility Modulation (CCM) treatment to improve exercise tolerance and quality of life in CHF patients. The DIAMOND System is an implantable electrical stimulator for improving blood glucose levels and metabolic parameters in patients suffering from diabesity.
“We are excited about the opportunity to introduce novel, state of the art medical technologies such as the OPTIMIZER III and DIAMOND System to patients in the region” said Dr. Greg Collier, Managing Director of Vitality. “We believe that these technologies will improve available treatment and quality of care for heart failure and metabolic patients throughout these territories”.
About Impulse Dynamics - Impulse Dynamics is a medical device company dedicated to offering innovative solutions for treatment of Chronic Heart Failure. The Optimizer III with Cardiac Contractility Modulation (CCM) therapy is CE marked and is available in select excellence centers across Europe and Asia.
About MetaCure – MetaCure is a medical device company dedicated to developing innovative minimally invasive Interventional Diabetology solutions for Type 2 Diabetes and its metabolic comorbidities. The Company’s leading product, The DIAMOND System has been shown to significantly improve glycemic and metabolic control while maintaining a clean safety profile. The DIAMOND System is CE approved since 2007 and is commercially available in selected excellence centers in Europe.